NYSEAMERICAN:PTN - Palatin Technologies Stock Price, Forecast & News

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, February, 11th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $4.48 million. During the same period last year, the firm earned ($0.02) earnings per share. View Palatin Technologies' Earnings History.

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Palatin Technologies.

3 brokerages have issued 1 year price objectives for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' share price to reach $3.67 in the next twelve months. This suggests a possible upside of 511.1% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

News coverage about PTN stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Palatin Technologies earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Palatin Technologies.

Some companies that are related to Palatin Technologies include Volpara Health Tech (VHT), Profound Medical (PRN), Akumin (AKU), Exagen (XGN), Senseonics (SENS), Renalytix Ai (RENX), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1), Oncimmune (ONC), Sernova (SVA), GeneNews (GEN) and SQI Diagnostics (SQD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AVEO Pharmaceuticals (AVEO), Progenics Pharmaceuticals (PGNX), ImmunoGen (IMGN), Actinium Pharmaceuticals (ATNM), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX) and Novavax (NVAX).

Palatin Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.55%), Acadian Asset Management LLC (1.42%), Geode Capital Management LLC (1.19%), Strs Ohio (0.34%), AQR Capital Management LLC (0.32%) and Bank of New York Mellon Corp (0.24%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.

PTN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, Oxford Asset Management LLP and California Public Employees Retirement System. View Insider Buying and Selling for Palatin Technologies.

PTN stock was purchased by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Virtu Financial LLC, Strs Ohio, Geode Capital Management LLC, Banque Cantonale Vaudoise, Barclays PLC and UBS Group AG. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTN stock can currently be purchased for approximately $0.60.

Palatin Technologies has a market capitalization of $137.54 million. Palatin Technologies employs 19 workers across the globe.View Additional Information About Palatin Technologies.

The official website for Palatin Technologies is http://www.palatin.com/.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.